2023 Q3 Form 10-Q Financial Statement
#000152828723000034 Filed on August 08, 2023
Income Statement
| Concept | 2023 Q3 | 2023 Q2 |
|---|---|---|
| Revenue | $16.43M | $16.51M |
| YoY Change | 47.23% | 61.86% |
| Cost Of Revenue | $4.194M | $4.538M |
| YoY Change | 31.39% | 65.98% |
| Gross Profit | $12.23M | $11.97M |
| YoY Change | 53.58% | 60.35% |
| Gross Profit Margin | 74.47% | 72.51% |
| Selling, General & Admin | $13.39M | $14.48M |
| YoY Change | 6.65% | 13.41% |
| % of Gross Profit | 109.44% | 120.97% |
| Research & Development | $4.795M | $5.343M |
| YoY Change | -14.54% | -5.75% |
| % of Gross Profit | 39.2% | 44.63% |
| Depreciation & Amortization | $100.0K | $100.0K |
| YoY Change | 0.0% | 0.0% |
| % of Gross Profit | 0.82% | 0.84% |
| Operating Expenses | $18.18M | $19.83M |
| YoY Change | 0.1% | 7.52% |
| Operating Profit | -$5.950M | -$7.854M |
| YoY Change | -41.66% | -28.43% |
| Interest Expense | $2.191M | $2.125M |
| YoY Change | 14.95% | 14.74% |
| % of Operating Profit | ||
| Other Income/Expense, Net | $115.0K | $122.0K |
| YoY Change | -211.65% | -243.53% |
| Pretax Income | -$7.260M | -$9.124M |
| YoY Change | -38.4% | -28.1% |
| Income Tax | $0.00 | $0.00 |
| % Of Pretax Income | ||
| Net Earnings | -$7.257M | -$9.124M |
| YoY Change | -38.42% | -28.1% |
| Net Earnings / Revenue | -44.18% | -55.26% |
| Basic Earnings Per Share | -$0.28 | -$0.36 |
| Diluted Earnings Per Share | -$0.28 | -$0.36 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 25.86M shares | 25.41M shares |
| Diluted Shares Outstanding | 26.02M shares | 25.47M shares |
Balance Sheet
| Concept | 2023 Q3 | 2023 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $61.30M | $63.57M |
| YoY Change | -28.23% | -31.21% |
| Cash & Equivalents | $9.717M | $7.855M |
| Short-Term Investments | $51.60M | $55.72M |
| Other Short-Term Assets | $1.600M | $2.050M |
| YoY Change | -36.03% | -35.13% |
| Inventory | $9.759M | $10.01M |
| Prepaid Expenses | ||
| Receivables | $11.28M | $10.88M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $83.97M | $86.51M |
| YoY Change | -19.54% | -23.08% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $949.0K | $976.0K |
| YoY Change | 6.15% | 2.63% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $15.00K | $21.00K |
| YoY Change | -28.57% | 0.0% |
| Total Long-Term Assets | $15.33M | $15.72M |
| YoY Change | -4.83% | 158.57% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $83.97M | $86.51M |
| Total Long-Term Assets | $15.33M | $15.72M |
| Total Assets | $99.30M | $102.2M |
| YoY Change | -17.58% | -13.76% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $1.207M | $1.807M |
| YoY Change | 2.72% | 20.23% |
| Accrued Expenses | $10.04M | $8.182M |
| YoY Change | 32.93% | 17.52% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $12.82M | $11.51M |
| YoY Change | 36.08% | 0.94% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $55.89M | $54.85M |
| YoY Change | 7.57% | 7.52% |
| Other Long-Term Liabilities | $14.20M | $14.64M |
| YoY Change | -9.52% | 354.36% |
| Total Long-Term Liabilities | $55.89M | $54.85M |
| YoY Change | 7.57% | 7.52% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $12.82M | $11.51M |
| Total Long-Term Liabilities | $55.89M | $54.85M |
| Total Liabilities | $82.94M | $81.01M |
| YoY Change | 7.62% | 23.41% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$497.6M | -$490.4M |
| YoY Change | 8.24% | 9.49% |
| Common Stock | $26.00K | $26.00K |
| YoY Change | 4.0% | 4.0% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $16.36M | $21.23M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $99.30M | $102.2M |
| YoY Change | -17.58% | -13.76% |
Cashflow Statement
| Concept | 2023 Q3 | 2023 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$7.257M | -$9.124M |
| YoY Change | -38.42% | -28.1% |
| Depreciation, Depletion And Amortization | $100.0K | $100.0K |
| YoY Change | 0.0% | 0.0% |
| Cash From Operating Activities | -$2.300M | -$4.360M |
| YoY Change | -67.03% | -59.09% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $10.00K | $0.00 |
| YoY Change | -132.26% | -100.0% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $4.200M | $5.300M |
| YoY Change | -40.0% | -36.9% |
| Cash From Investing Activities | $4.190M | $5.300M |
| YoY Change | -39.88% | -35.65% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -30.00K | 195.0K |
| YoY Change | 275.0% | -69.29% |
| NET CHANGE | ||
| Cash From Operating Activities | -2.300M | -4.360M |
| Cash From Investing Activities | 4.190M | 5.300M |
| Cash From Financing Activities | -30.00K | 195.0K |
| Net Change In Cash | 1.860M | 1.135M |
| YoY Change | -13385.71% | -163.51% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$2.300M | -$4.360M |
| Capital Expenditures | $10.00K | $0.00 |
| Free Cash Flow | -$2.310M | -$4.360M |
| YoY Change | -66.73% | -58.45% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2022Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2022Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.52 | |
| CY2022Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.52 | |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.99 | ||
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.99 | ||
| CY2022Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
24503552 | shares |
| CY2022Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
24503552 | shares |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
25285933 | shares | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
25285933 | shares | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
24406100 | shares | |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
24406100 | shares | |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
|
0 | usd |
| CY2023Q1 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
146000 | usd |
| CY2023Q1 | us-gaap |
Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
|
0 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
2125000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
27490000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9124000 | usd |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
5000 | usd |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
240000 | usd |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
|
0 | usd |
| CY2023Q2 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
41000 | usd |
| CY2023Q2 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
2655000 | usd |
| CY2022Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-710000 | usd |
| CY2022Q1 | us-gaap |
Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
|
0 | usd |
| CY2022Q1 | npce |
Adjustments To Additional Paid In Capital Change In Early Exercise Liability
AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability
|
-2000 | usd |
| CY2022Q1 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
1488000 | usd |
| CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
62823000 | usd |
| CY2022Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12690000 | usd |
| CY2022Q2 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-469000 | usd |
| CY2022Q2 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
679000 | usd |
| CY2022Q2 | us-gaap |
Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
|
0 | usd |
| CY2022Q2 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
47000 | usd |
| CY2022Q2 | npce |
Adjustments To Additional Paid In Capital Change In Early Exercise Liability
AdjustmentsToAdditionalPaidInCapitalChangeInEarlyExerciseLiability
|
-1000 | usd |
| CY2022Q2 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
2603000 | usd |
| CY2022Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
52902000 | usd |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-19499000 | usd | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-24151000 | usd | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4780000 | usd | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
4091000 | usd | |
| us-gaap |
Depreciation
Depreciation
|
96000 | usd | |
| us-gaap |
Depreciation
Depreciation
|
153000 | usd | |
| us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
133000 | usd | |
| us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
128000 | usd | |
| npce |
Increase Decrease In Non Cash Interest Expense
IncreaseDecreaseInNonCashInterestExpense
|
494000 | usd | |
| npce |
Increase Decrease In Non Cash Interest Expense
IncreaseDecreaseInNonCashInterestExpense
|
411000 | usd | |
| us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
1314000 | usd | |
| us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
632000 | usd | |
| us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
702000 | usd | |
| us-gaap |
Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
|
1343000 | usd | |
| us-gaap |
Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
|
-695000 | usd | |
| us-gaap |
Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
|
-109000 | usd | |
| us-gaap |
Inventory Write Down
InventoryWriteDown
|
88000 | usd | |
| us-gaap |
Inventory Write Down
InventoryWriteDown
|
169000 | usd | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
3395000 | usd | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
1384000 | usd | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
389000 | usd | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
766000 | usd | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1061000 | usd | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
841000 | usd | |
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-215000 | usd | |
| us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
93000 | usd | |
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
769000 | usd | |
| us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-468000 | usd | |
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
0 | usd | |
| us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
31000 | usd | |
| CY2023Q2 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-490400000 | usd |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-14100000 | usd | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-22100000 | usd | |
| CY2023Q2 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
63600000 | usd |
| npce |
Debt Instrument Covenant Minimum Annual Net Revenue
DebtInstrumentCovenantMinimumAnnualNetRevenue
|
45000000 | usd | |
| CY2023Q2 | npce |
Debt Instrument Covenant Minimum Cash And Cash Equivalents Required After Completion Of Ipo
DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO
|
5000000 | usd |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim condensed financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. The Company uses significant judgment when making estimates related to the valuation of deferred tax assets and related valuation allowances and provision for excess and obsolete inventories. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div> | ||
| us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, short-term investments and accounts receivable to the extent of the amounts recorded on the balance sheets. The Company’s cash is invested in major financial institutions in the United States. Deposits in these financial institutions may exceed federally insured limits, and the Company is exposed to credit risk on deposits in the event of default of the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation. The Company’s cash equivalents are invested in money market funds.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable are due from a variety of health care organizations in the United States. For the three and six months ended June 30, 2023 and 2022, there were no customers that represented 10% or more of revenue. As of June 30, 2023 and December 31, 2022, no customer represented 10% or more of the Company’s accounts receivable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks, including that its devices may not be approved or cleared or continue to be approved or cleared for marketing by governmental authorities or be successfully marketed for expanded indications. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and speed and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence on healthcare providers to prescribe initial implants and replacements, dependence upon third-party payors to provide adequate coverage and reimbursement, dependence on key personnel, single-source suppliers and vendors in connection with the manufacture of its products, concentration of CECs and epileptologists, obtaining, maintaining, protecting, enforcing, and defending intellectual property rights and proprietary technology, product liability claims, legal proceedings, and compliance with government regulations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s medical devices require approvals or clearances from the U.S. Food and Drug Administration, or the FDA, or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If approvals or clearances were withdrawn by the FDA for the Company’s current products or if such approvals or clearances were denied or delayed for future products, product updates, or expanded indications for use, it would have a material adverse impact on the Company.</span></div> | ||
| CY2021Q2 | npce |
Research And Development Arrangement With Federal Government Term
ResearchAndDevelopmentArrangementWithFederalGovernmentTerm
|
P5Y | |
| CY2021Q2 | npce |
Research And Development Arrangement With Federal Government Total Estimated Cost
ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost
|
9300000 | usd |
| CY2021Q2 | npce |
Research And Development Arrangement With Federal Government Estimated Cost For Subawards
ResearchAndDevelopmentArrangementWithFederalGovernmentEstimatedCostForSubawards
|
5500000 | usd |
| CY2021Q2 | npce |
Research And Development Arrangement With Federal Government Approved Funding Year1
ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingYear1
|
800000 | usd |
| CY2021Q2 | npce |
Research And Development Arrangement With Federal Government Approved Funding Subawards Year1
ResearchAndDevelopmentArrangementWithFederalGovernmentApprovedFundingSubawardsYear1
|
400000 | usd |
| CY2022Q3 | npce |
Research And Development Arrangement With Federal Government Approval For Funding Year2
ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2
|
2600000 | usd |
| CY2022Q3 | npce |
Research And Development Arrangement With Federal Government Approval For Funding Subawards Year2
ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2
|
1600000 | usd |
| CY2023Q2 | npce |
Research And Development Arrangement With Federal Government Approval For Funding Year2
ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingYear2
|
3000000 | usd |
| CY2023Q2 | npce |
Research And Development Arrangement With Federal Government Approval For Funding Subawards Year2
ResearchAndDevelopmentArrangementWithFederalGovernmentApprovalForFundingSubawardsYear2
|
1500000 | usd |
| CY2023Q2 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
7534000 | usd |
| CY2023Q2 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
55716000 | usd |
| CY2023Q2 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
63250000 | usd |
| CY2022Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
6075000 | usd |
| CY2022Q4 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
70804000 | usd |
| CY2022Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
76879000 | usd |
| CY2023Q2 | us-gaap |
Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
|
0 | usd |
| CY2022Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
71900000 | usd |
| CY2023Q2 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
3600000 | usd |
| CY2023Q2 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
789000 | usd |
| CY2023Q2 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
5625000 | usd |
| CY2023Q2 | us-gaap |
Inventory Net
InventoryNet
|
10014000 | usd |
| CY2023Q2 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
9797000 | usd |
| CY2023Q2 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
8821000 | usd |
| CY2023Q2 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
976000 | usd |
| CY2023Q2 | us-gaap |
Depreciation
Depreciation
|
100000 | usd |
| CY2023Q2 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
6637000 | usd |
| CY2023Q2 | npce |
Accrued Inventory Liability Current
AccruedInventoryLiabilityCurrent
|
550000 | usd |
| CY2023Q2 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
366000 | usd |
| CY2023Q2 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
629000 | usd |
| CY2023Q2 | npce |
Accrued And Employee Related Liabilities Current
AccruedAndEmployeeRelatedLiabilitiesCurrent
|
8182000 | usd |
| CY2022Q3 | npce |
Operating Lease Renewal Term
OperatingLeaseRenewalTerm
|
P5Y | |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
1387000 | usd |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
2857000 | usd |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
2942000 | usd |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
3031000 | usd |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
3122000 | usd |
| CY2023Q2 | npce |
Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
|
8232000 | usd |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
21571000 | usd |
| CY2023Q2 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
5408000 | usd |
| CY2023Q2 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
16163000 | usd |
| CY2023Q2 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
1519000 | usd |
| CY2023Q2 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
14644000 | usd |
| CY2023Q2 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
700000 | usd |
| CY2023Q2 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P7Y | |
| CY2023Q2 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.085 | |
| us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1400000 | usd | |
| CY2022Q3 | us-gaap |
Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
|
2400000 | usd |
| CY2022Q3 | npce |
Purchase Obligation Minimum Increase Percentage In Next Two Years
PurchaseObligationMinimumIncreasePercentageInNextTwoYears
|
0.10 | |
| CY2023Q2 | npce |
Indemnification Liability Officers And Directors
IndemnificationLiabilityOfficersAndDirectors
|
0 | usd |
| CY2022Q4 | npce |
Indemnification Liability Officers And Directors
IndemnificationLiabilityOfficersAndDirectors
|
0 | usd |
| CY2023Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
| CY2023Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2022 | us-gaap |
Dividends Common Stock Cash
DividendsCommonStockCash
|
0 | usd |
| CY2023Q2 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
7806904 | shares |
| CY2022Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
7076678 | shares |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3446583 | shares |
| CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
3.61 | |
| CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y21D | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
314801 | shares | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
3.21 | ||
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
181742 | shares | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0.03 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
122141 | shares | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
4.07 | ||
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3457501 | shares |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
3.75 | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P5Y2M15D | ||
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
2057141 | shares |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
3.03 | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P4Y9M21D | ||
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
3457501 | shares |
| CY2023Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
3.75 | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P5Y2M15D | ||
| CY2023Q2 | npce |
Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Repurchase
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase
|
53599 | shares |
| CY2022Q4 | npce |
Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Repurchase
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase
|
78389 | shares |
| CY2021Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
|
0.85 | |
| CY2021Q2 | npce |
Employee Stock Purchase Plan Length Of Offering Period
EmployeeStockPurchasePlanLengthOfOfferingPeriod
|
P6M | |
| CY2023Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2655000 | usd |
| CY2022Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2603000 | usd |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4780000 | usd | |
| CY2023Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2655000 | usd |
| CY2022Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2603000 | usd |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
4780000 | usd | |
| CY2023Q2 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
19000000 | usd |
| us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y6M | ||
| us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd | |
| CY2023Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2022Q2 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-9124000 | usd |
| CY2022Q2 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-12690000 | usd |
| us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-19499000 | usd | |
| CY2023Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
25472526 | shares |
| CY2023Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
25472526 | shares |
| CY2022Q2 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
24503552 | shares |
| us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
24406100 | shares | |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
24406100 | shares | |
| CY2023Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.36 | |
| CY2023Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.36 | |
| CY2022Q2 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.52 | |
| us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.77 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.99 | ||
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6614192 | shares | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5678206 | shares |
